News Related to GLP-1 receptor agonist

Related coverage linked through entity extraction aliases.

Drug Discovery Patent Filings Span Protein Degradation, Ion Channels, and Emerging Targets

Feb 25, 2025

Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.

Eli Lilly Advances Weight-Loss Pipeline with Retatrutide Results and Orforglipron Stockpiling

Dec 12, 2025

Eli Lilly reported positive Phase 3 results for retatrutide showing up to 71.2 lbs average weight loss, while stockpiling $1.5 billion of oral drug orforglipron ahead of anticipated FDA approval in April 2026.